On February 10, the U.S. Court of Appeals for the Federal Circuit (CAFC) affirmed a decision by the U.S. District Court for the District of New Jersey, explaining that the district court did not err in finding several Adapt Pharma patents obvious. The asserted claims relate to U.S. Patent Nos. 9,468,747; 9,561,177; 9,629,965; and 9,775,838 (collectively, the “patents-in-suit”). The patents-in-suit claim methods of treating opioid overdose by intranasal administration of a naloxone formulation, as well as devices for intranasal administration. Naloxone is the active ingredient in Adapt’s NARCANâ Nasal Spray and is an opioid receptor antagonist, thus helping reverse the effects of opioid overdose. The opinion was authored by Judge Kara Stoll; Judge Pauline Newman dissented.
Recent Posts
- A New Era of Copyright Litigation in Hollywood: Revisiting Pirates of the Caribbean One Year Later
- Federal Circuit Vacates TTAB Decision as Arbitrary and Capricious
- ‘I Want to Thank You’: Who and What IP Stakeholders are Giving Thanks for This Year
- SCOTUS Declines Solving Circuit Split on Awarding Avoided Costs in Trade Secret Cases
- Supreme Court Again Denies Inventor’s Bid to End Alice/Mayo